Login to Your Account



Clinic Roundup


Friday, February 17, 2012
• Curis Inc., of Lexington, Mass., said partner Debiopharm Group, of Lausanne, Switzerland, initiated a Phase Ib expansion study of Debio 0932, a heat-shock protein 90 inhibitor that recently completed a Phase Ia dose-escalation study evaluating safety and maximum-tolerated dose.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription